Want to see HK:6609 full AI Analyst Report?
6609 Stock Chart & Stats
HK$54.60
-HK$0.05(-0.24%)
At close: 4:00 PM EST
HK$54.60
-HK$0.05(-0.24%)
Day’s Range― - ―
52-Week RangeHK$35.00 - HK$71.25
Previous CloseN/A
Volume1.35K
Average Volume (3M)127.28K
Market Cap
HK$1.94B
Enterprise ValueHK$1.20K
Total Cash (Recent Filing)HK$786.48M
Total Debt (Recent Filing)HK$42.72M
Price to Earnings (P/E)19.5
Beta1.45
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.18
Shares Outstanding31,565,804
10 Day Avg. Volume119,990
30 Day Avg. Volume127,280
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.61
Price to Sales (P/S)4.47
P/FCF Ratio13.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.91
Revenue Forecast (FY)HK$546.64M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And GrowthThe substantial expansion in revenue indicates stronger product adoption and commercial scale. If maintained, a larger operating base can support investment in medical-device development, broaden market reach, and improve fixed-cost absorption.
Profitability And Cash Flow TurnaroundThe simultaneous return to operating profit, net profit and positive free cash flow suggests improved operating leverage and cash conversion. Sustaining these gains would strengthen internal funding capacity and reduce dependence on external capital.
Low Financial LeverageVery low leverage limits interest and refinancing pressure, preserving financial flexibility for research, manufacturing capacity and commercial expansion. The sizable equity base also provides a buffer if medical-device investment cycles require additional funding.
Bears Say
Unproven Profitability DurabilityThe latest profit improvement is encouraging but has not yet been demonstrated across multiple reporting periods. Continued earnings execution is needed to establish that margins reflect durable demand and operating efficiency rather than a one-period recovery.
Volatile Cash GenerationLarge year-to-year swings indicate that cash conversion remains sensitive to operating or investment needs. Persistent variability could constrain self-funded growth and make liquidity planning more difficult even though the latest year showed strong cash generation.
Historically Weak ReturnsRecent positive returns remain modest relative to the equity committed and follow periods in which losses reduced shareholder value. Future reinvestment requirements could continue to weigh on returns unless growth converts consistently into higher-margin earnings.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H News
6609 FAQ
What was Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price range in the past 12 months?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H lowest stock price was HK$35.00 and its highest was HK$71.25 in the past 12 months.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap is HK$1.94B.
When is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 8 days.
How were Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s earnings last quarter?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H released its earnings results on Mar 26, 2026. The company reported HK$0.941 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Shanghai Heartcare Medical Technology Corp. Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price is currently Overvalued.
Does Shanghai Heartcare Medical Technology Corp. Ltd. Class H pay dividends?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H does not currently pay dividends.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Heartcare Medical Technology Corp. Ltd. Class H have?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H has 31,565,804 shares outstanding.
What happened to Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price movement after its last earnings report?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H reported an EPS of HK$0.941 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.091%.
Which hedge fund is a major shareholder of Shanghai Heartcare Medical Technology Corp. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6609
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.12%
Trailing 12-Months
Company Description
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
null
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) Earnings & Revenues
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
MicroPort CardioFlow Medtech Corp.
―
Venus Medtech (Hangzhou), Inc. Class H
―